Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$3.90 - $23.86
Next Earnings Date
May 09 2025
Next Earnings Date
May 09 2025
Latest price
Market Cap | $1.20B |
EV | $541.86M |
Shares Outstanding | 160.84M |
Beta | 3.14 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $15.17 |
P/E 2025E | 18.04x |
P/Revenue 2025E | 2.10x |
Revenue | -15.90% |
EPS | 62.60% |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | -22.50% |
EPS | - |
Operating Cash Flow | 25.10% |
Free Cash Flow | - |
Gross Margin 2025E | 96.90% |
Net Profit Margin 2025E | 14.28% |
ROE 2025E | - |
ROCE 2024 | - |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Novavax, Inc.
NVAX
Sector
Healthcare
Industry
Biotechnology
CEO
Jacobs, John
Employees
952
Website
www.novavax.comIPO Date
1995-12-05
Headquarters
700 Quince Orchard Road, Gaithersburg, Maryland, 20878, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved